Articles tagged with Ovarian Cancer
Researchers at Mayo Clinic have found a combination of drugs that destroys 70% of chemotherapy-resistant ovarian cancer cells. The discovery highlights the role of molecule RhoB in tumor response and may help identify patients who benefit from this therapy.
A tiny genetic variation in the KRAS oncogene can predict ovarian cancer outcomes and response to treatment, with women carrying the variant being three times more resistant to standard chemotherapy. The biomarker also increases the risk of poor outcomes in other types of cancer.
Researchers at University of Guelph discovered a peptide that regresses established late-stage tumours in mouse models of ovarian cancer, improving survival rates. The peptide enhances chemotherapy drug delivery, allowing for lower doses and reduced side effects.
A large pad of fat cells in the abdomen provides nutrients that promote the spread and growth of ovarian cancer. Cancer cells reprogram their metabolism to thrive on lipids acquired from fat cells, leading to rapid tumor growth.
A new therapy uses folate receptors as a front door to deliver chemotherapeutic agents directly to cancer cells, improving effectiveness while reducing side effects. The strategy has shown a 72% improvement in progression-free survival for women with the most folate receptor overexpression.
Women undergoing IVF treatment have a higher risk of developing borderline ovarian tumours and an increased risk of malignant ovarian cancer compared to those not treated with IVF. The long-term risks are significant enough to warrant further research.
A new genome sequencing method has identified mutations in 12 genes linked to inherited ovarian and related cancers. The test, called BROCA, could become a single test for screening broad range of cancers.
The Terry Fox Research Institute is funding a $5-million program to develop new biomarkers and treatments for ovarian cancer. The program aims to identify new approaches to diagnose and manage the disease, which currently affects one in four women diagnosed with ovarian cancer.
A study found that women with BRCA2 genetic mutations experienced significantly better overall survival rates (61") compared to those without the mutation (25"). Additionally, BRCA2-mutated patients demonstrated longer progression-free survival durations and higher primary chemotherapy sensitivity rates
Women with high-grade ovarian cancer who have BRCA2 genetic mutations live longer and respond better to platinum-based chemotherapy. The tumors are more vulnerable to DNA-damaging agents, which could lead to effective treatment combinations.
Researchers at Stanford University School of Medicine have identified a unique gene fusion in ovarian cancer that could enable early detection and targeted therapies. The fusion, involving genes ESRRA and C11orf20, was found in 15% of aggressive ovarian cancer cases.
A recurrent gene fusion between ESRRA and C11orf20 was found in about 15% of serous ovarian cancer cases, suggesting a potential marker for early detection. The discovery sheds light on how these deadly tumors develop and spread.
A new multispectral fluorescence imaging system has been developed to localize cancer cells during surgery, enabling surgeons to detect small clusters of tumor cells that might otherwise go undetected. In a study on nine patients with ovarian cancer, the system successfully detected and removed all cancer cells in eight cases.
A recent study found that depression is a significant barrier to preventive health screening among Latina breast cancer survivors. The research revealed that Hispanic breast cancer patients are more depressed than their non-Hispanic counterparts and have lower rates of screening for colorectal and ovarian cancers.
A new technology developed by Purdue University researchers allows surgeons to detect small clusters of ovarian cancer cells, leading to improved removal rates. The technique uses a fluorescent imaging agent that 'homed' to cancer cells, illuminating their location during surgery.
Researchers at Moffitt Cancer Center have identified a molecular pathway that may play a key role in the evolution of chemotherapy resistance in ovarian cancer. The 'BCL2 antagonist of cell death' (BAD) pathway shows promise as a biomarker to identify patients with high-risk ovarian cancer and potentially reverse chemo-resistance.
A new hybrid imaging device combining photoacoustic imaging, optical coherence tomography, and pulse-echo ultrasound has been developed to diagnose early-stage ovarian cancer. The device was tested on both pig and human ovarian tissue, correctly identifying malignant tumors in initial tests.
Researchers discovered that certain BRCA1 mutations causing hyper-recombination contribute to breast and ovarian cancers by disrupting genomic stability. Targeted therapies may be developed by disrupting ubiquitination to prevent hyper-recombination and kill cancer cells.
Scientists at the University of Strathclyde have developed a program to test plant extracts for their ability to stop ovarian cancer cells from growing. Initial tests show promising results, with several plant extracts killing tumor samples taken from cancer patients.
A recent UCSF study analyzes the long-term effects of chemotherapy on women's reproductive health, finding that younger women are more likely to experience early menopause and infertility. The research provides new insights for patients and clinicians, enabling more strategic and personalized counseling about fertility preservation.
A phase 2 trial found that olaparib reduced tumor size in 41% of patients with ovarian cancer and no BRCA gene mutations. The treatment was generally well-tolerated and offered new hope for ovarian cancer treatment targeting DNA repair mechanisms.
Rush researchers identified a molecule, an antibody, in the bloodstream of infertile women that could be used to screen for high-risk individuals or those with early-stage ovarian cancer. Significant levels of mesothelin antibodies were found in women with premature ovarian failure and ovulatory dysfunction.
Researchers developed second-generation engineered T cells that successfully target and kill ovarian cancer cells in immune-deficient mice. The new technology overcomes limitations of first-generation approaches, showing improved persistence and survival signals for the engineered T cells.
A study found that many physicians do not follow guidelines for breast and ovarian cancer counseling and testing, affecting high-risk women who may miss out on life-saving interventions. Physicians were more likely to follow guidelines when accurately estimating patients' ovarian cancer risks.
Researchers at the University of Michigan Comprehensive Cancer Center have found that mesenchymal stem cells, normally used for wound healing, are recruited by cancer stem cells to fuel ovarian cancer growth. By blocking this process with a protein called BMP2, researchers may have discovered a potential therapy for ovarian cancer.
Researchers at The Pennsylvania State University College of Medicine discovered that low-dose naltrexone (LDN) has a potent antitumor effect on human ovarian cancer. Combining LDN with chemotherapy resulted in an additive inhibitory action on tumorigenesis, reducing DNA synthesis and cell replication.
Researchers from the Broad Institute and Harvard identified genes essential for ovarian tumor growth, including PAX8, which is altered in nearly one-fifth of surveyed tumors. The study's findings have implications for cancer research, suggesting that classification based on genetic mutations may be more revealing than tissue origin.
A multi-institutional study published in Nature reveals the genetic overview of ovarian cancer, showing mutations in one gene and frequent structural changes that contribute to its development. The findings could lead to better treatments for this aggressive form of cancer.
Using mice, researchers identified differences in viscoelastic properties between early and advanced stages of ovarian cancer. They found that benign cells are stiffer and more viscous than malignant cells, which is consistent with previous studies on other types of cancer.
Researchers from UNC Lineberger have contributed to a comprehensive view of cancer genes in ovarian cancer, identifying sets of genes associated with patient survival patterns and potential therapeutic targets.
The study analyzed over 300 tumor samples and found that 96% had mutated TP53 genes, while BRCA1 and BRCA2 were mutated in 30% of patients. The researchers identified a set of genes associated with worse or better patient outcomes, predicting survival rates.
The study provides a comprehensive view of cancer genes for any cancer type to date, identifying patterns in gene expression that predict patient survival. The results support four distinct subtypes of the disease based on genomic changes and highlight potential therapeutic targets using existing drugs.
Researchers have found that ovarian cancer cells use brute force to invade surrounding tissues and organs. The study identified key proteins involved in this process, providing a potential target for future treatments.
Researchers found that PET/CT imaging with the radiotracer 18F-FDG successfully detected 84% of benign and malignant tumors in patients with adnexal masses. This technology helps predict cancer stage and provide better treatment options for women diagnosed with ovarian cancer.
Researchers identified genetic mutations associated with lower cancer risk (e.g., MSH6) and increased risk (e.g., MLH1, MSH2) for ovarian and endometrial cancer in individuals with Lynch syndrome. The study provides age- and gene-specific risk estimates for each tumor type.
A clinical trial of 78,216 women found no reduction in ovarian cancer death risk with screening. Instead, screenings led to more invasive medical procedures and higher complication rates. The study suggests that annual screening may not be effective in detecting cancers early enough to reduce mortality.
New research finds that women with BRCA1/2 mutations who undergo prophylactic oophorectomy and take short-term HRT have a decreased risk of developing breast cancer. However, the procedure also increases the risk of early menopause and related quality-of-life issues.
Researchers developed a new test that identifies specific tumour types in ovarian cancer patients, enabling doctors to personalize treatment programmes. The test may improve survival rates by identifying aggressive forms of cancer that respond well to targeted drug treatments.
New studies released by ASCO highlight advances in cervical cancer screening, ovarian cancer detection, and prostate cancer risk prediction. The studies also explore genetic biomarkers for chemotherapy-induced neuropathy and potential treatments for relapsed ovarian cancer.
Researchers have found that over-expression of motor protein km23-1 can block human ovarian tumor growth, leading to eventual cancer cell death. This discovery offers promise for new therapies to treat ovarian cancer, a disease affecting U.S. women with an estimated 21,880 new cases and 13,850 deaths in 2010.
Researchers at Dana-Farber Cancer Institute have developed a laboratory model that mimics the process by which fallopian tube cells may morph into cancer cells. The model demonstrates that HGSOC begins in the fallopian tubes, providing powerful evidence for this theory.
An experimental drug called NVP-BEZ235 blocks a crucial cancer cell signaling pathway, slowing ovarian cancer growth and increasing survival in an ovarian cancer mouse model. The drug also re-sensitizes resistant cancer cells to platinum chemotherapy, offering new hope for fighting drug resistance.
Researchers at Oregon Health & Science University discovered a new approach to prevent ovarian cancer in high-risk women while maintaining fertility. The treatment involves removing the ovarian surface epithelium layer, which has no known function, without affecting ovary function or overall animal health.
A study published at the AACR Annual Meeting found that women with ovarian cancer and BRCA2 mutations had improved survival rates compared to those with BRCA1 mutations or no mutations. The five-year survival rate for women with BRCA2 mutations was 61%, significantly higher than those without mutations (36%). Further research is needed...
Researchers have developed nanoparticles loaded with siRNA to silence cancer-promoting genes in ovarian cancer, selectively shrinking or destroying tumors. The nanoparticles use high-density lipoprotein (HDL) as a delivery vehicle, which is taken up by cancer cells and not healthy tissue.
Philanthropists Foster and Lynn Friess are tripling-match donations up to $100,000 for TGen's unTEAL a cure event. The total raised will support groundbreaking research on ovarian cancer cases.
A new study published in Journal of Clinical Oncology found that adding targeted therapy bevacizumab to treatment for advanced ovarian cancer patients is not cost-effective. The researchers analyzed a clinical trial and found that the additional survival benefit was offset by high costs.
Researchers at York University have identified a key role for microRNA 376c in allowing ovarian cancer cells to thrive despite chemotherapy. By targeting the receptor ALK7, this microRNA enables cancer cells to survive and resist cell death.
Research using primary care records reveals that GPs often take more than a month to record an ovarian cancer diagnosis after receiving notification from specialists. In fact, one in ten cases took over four weeks, while 11% of records showed incorrect or premature diagnoses.
Scientists at Georgia Institute of Technology have found a regulatory RNA called miR-429 that can induce metastatic cancer cells to convert back into less invasive forms. This discovery may allow physicians to treat ovarian cancer more effectively with traditional chemotherapy.
African American women have lower incidence rates yet poorer survival rates for ovarian cancer compared to women of other races. The study aims to determine how risk factors differ between African American and white women, with the goal of preventing this deadly disease.
Researchers at Georgia Tech have developed a new treatment system that uses magnetic nanoparticles to capture free-floating cancer cells, slowing tumor progression in humans. The system aims to reduce chemotherapy side effects by removing the primary source of metastasis.
Survival rates for breast, ovarian, colorectal, and lung cancer are higher in Australia, Canada, and Sweden compared to the UK and Denmark. International differences narrowed for breast cancer, but significant disparities remain in other cancers.
Preethi Gunaratne's research aims to unleash the body's natural cancer-fighting agents using microRNAs, which have been shown to suppress the growth of cancer cells. Gold nanoparticles are being explored as a potential carrier for these molecules, offering a promising treatment for ovarian cancer with minimal side effects.
Researchers at the University of Gothenburg have confirmed that ovarian cancer tissue and healthy tissue smell different, using an electronic nose. The discovery has major practical implications for early detection and treatment of ovarian cancer.
Scientists have identified age-related gene-specific accumulation of DNA methylation that suppresses the critical TGF-beta pathway contributing to ovarian carcinogenesis. This finding provides crucial information for future translational research and may lead to targeted therapeutic interventions.
Researchers at Duke University Medical Center found evidence of epigenetics in ovarian cancer, specifically DNA methylation affecting the TGF-beta signaling pathway. This deregulation contributes to tumor growth and metastasis, highlighting a potential target for epigenetic therapies.
Researchers found that ovarian cancer screening can only slightly reduce mortality rates, highlighting the need for prevention and better treatments. For high-risk women, targeted screening may offer more hope in reducing deaths from ovarian cancer.
Incorporating ovarian cancer subtypes into screening models reduces predicted mortality rates. However, catching slower-growing cancers won't significantly impact deaths compared to more lethal tumors.
AnaLisa DiFeo will investigate microRNA profiles and their association with chemotherapy sensitivity in ovarian cancer tumors. Her research aims to identify new drug targets for overcoming chemoresistance and improving treatment outcomes.